A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Treeline Biosciences, Inc.
Bayer
Shanghai Henlius Biotech
Pfizer
Eli Lilly and Company
Pfizer
Boehringer Ingelheim
Astellas Pharma Inc
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Fate Therapeutics
Alterome Therapeutics, Inc.
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
Pfizer
Erasca, Inc.